QURE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against uniQure N.V. due to allegations of violations of federal securities laws, particularly concerning misleading statements and undisclosed information related to the company's Pivotal Study and BLA submission timeline [2][4]. Group 1: Allegations and Legal Actions - The complaint alleges that uniQure and its executives made false and misleading statements regarding the FDA's approval of the Pivotal Study design and downplayed the likelihood of delays in the BLA submission for AMT-130 [4]. - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the data from the Phase I/II AMT-130 studies would support a BLA submission, contradicting previous representations about the approval timeline [5]. - Following this disclosure, uniQure's share price fell by $33.40, or over 49%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [6]. Group 2: Investor Information - Investors who purchased uniQure securities between September 24, 2025, and October 31, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1]. - There is an April 13, 2026, deadline for investors to seek the role of lead plaintiff in the federal securities class action against uniQure [2]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [7].